Eric Leip

20.9k total citations · 10 hit papers
117 papers, 14.6k citations indexed

About

Eric Leip is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Eric Leip has authored 117 papers receiving a total of 14.6k indexed citations (citations by other indexed papers that have themselves been cited), including 87 papers in Hematology, 60 papers in Genetics and 22 papers in Rheumatology. Recurrent topics in Eric Leip's work include Chronic Myeloid Leukemia Treatments (62 papers), Chronic Lymphocytic Leukemia Research (60 papers) and Multiple Myeloma Research and Treatments (24 papers). Eric Leip is often cited by papers focused on Chronic Myeloid Leukemia Treatments (62 papers), Chronic Lymphocytic Leukemia Research (60 papers) and Multiple Myeloma Research and Treatments (24 papers). Eric Leip collaborates with scholars based in United States, Germany and Italy. Eric Leip's co-authors include Martin G. Larson, Daniel Levy, Ramachandran S. Vasan, Emelia J. Benjamin, Thomas J. Wang, Ralph B. D’Agostino, William B. Kannel, Philip A. Wolf, Donald M. Lloyd‐Jones and Peter W.F. Wilson and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Eric Leip

113 papers receiving 14.0k citations

Hit Papers

Impact of High-Normal Blood Pressure on the Risk of Cardi... 2001 2026 2009 2017 2001 2004 2003 2004 2002 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Impact of High-Normal Blood Pressure on the Risk of Cardiovascular Disease
    2001 1.5k citations Ramachandran S. Vasan, Martin G. Larson et al. profile →
  2. Lifetime Risk for Development of Atrial Fibrillation
    2004 1.5k citations Thomas J. Wang, Eric Leip et al. Circulation profile →
  3. Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality
    2003 1.5k citations Thomas J. Wang, Martin G. Larson et al. Circulation profile →
  4. Plasma Natriuretic Peptide Levels and the Risk of Cardiovascular Events and Death
    2004 1.2k citations Thomas J. Wang, Martin G. Larson et al. profile →
  5. Lifetime Risk for Developing Congestive Heart Failure
    2002 1.1k citations Martin G. Larson, Eric Leip et al. Circulation profile →
  6. Does the Relation of Blood Pressure to Coronary Heart Disease Risk Change With Aging?
    2001 981 citations Stanley S. Franklin, Martin G. Larson et al. Circulation profile →
  7. Prediction of Lifetime Risk for Cardiovascular Disease by Risk Factor Burden at 50 Years of Age
    2006 901 citations Eric Leip, Martin G. Larson et al. Circulation profile →
  8. Impact of Obesity on Plasma Natriuretic Peptide Levels
    2004 771 citations Thomas J. Wang, Martin G. Larson et al. Circulation profile →
  9. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study
    2001 757 citations Ramachandran S. Vasan, Martin G. Larson et al. profile →
  10. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
    2017 320 citations Jörge E. Cortes, Carlo Gambacorti‐Passerini et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eric Leip United States 36 9.9k 1.7k 1.5k 1.4k 1.3k 117 14.6k
Wolfram Doehner Germany 68 7.2k 0.7× 1.4k 0.8× 1.6k 1.1× 560 0.4× 2.2k 1.7× 296 18.7k
Stefan D. Anker Germany 76 11.6k 1.2× 2.2k 1.3× 2.0k 1.4× 657 0.5× 2.6k 2.0× 351 24.4k
Inder S. Anand United States 81 17.6k 1.8× 1.8k 1.1× 2.7k 1.8× 670 0.5× 2.9k 2.3× 420 23.2k
Eldrin F. Lewis United States 56 7.4k 0.8× 1.7k 1.0× 3.3k 2.2× 812 0.6× 3.7k 2.9× 223 16.8k
Wiek H. van Gilst Netherlands 68 11.8k 1.2× 1.7k 1.0× 2.4k 1.6× 396 0.3× 2.8k 2.1× 475 20.4k
Sunil Bhandari United Kingdom 39 4.4k 0.4× 1.7k 1.0× 1.7k 1.1× 292 0.2× 1.6k 1.3× 203 11.3k
Kosaku Nitta Japan 46 3.0k 0.3× 1.1k 0.7× 1.5k 1.0× 544 0.4× 2.3k 1.8× 598 14.8k
Dominique Arveiler France 65 6.0k 0.6× 1.3k 0.8× 4.4k 3.0× 2.3k 1.6× 2.6k 2.0× 247 15.7k
Kenneth Dickstein Norway 47 8.7k 0.9× 1.7k 1.0× 1.1k 0.8× 209 0.2× 1.1k 0.8× 166 11.9k
Kunitoshi Iseki Japan 58 2.9k 0.3× 945 0.6× 1.8k 1.2× 859 0.6× 2.2k 1.7× 321 13.1k

Countries citing papers authored by Eric Leip

Since Specialization
Citations

This map shows the geographic impact of Eric Leip's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Leip with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Leip more than expected).

Fields of papers citing papers by Eric Leip

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Leip. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Leip. The network helps show where Eric Leip may publish in the future.

Co-authorship network of co-authors of Eric Leip

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Leip. A scholar is included among the top collaborators of Eric Leip based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Leip. Eric Leip is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Smith, B. Douglas, Tim H. Brümmendorf, Gail J. Roboz, et al.. (2024). Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study. Leukemia Research. 139. 107481–107481. 1 indexed citations
4.
Prince, H. Miles, Nizar J. Bahlis, Paula Rodríguez‐Otero, et al.. (2024). MagnetisMM-3: Long-Term Update and Efficacy and Safety of Less Frequent Dosing of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma. Blood. 144(Supplement 1). 4738–4738. 5 indexed citations
5.
Gambacorti‐Passerini, Carlo, Tim H. Brümmendorf, Elisabetta Abruzzese, et al.. (2024). Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial. Leukemia. 38(10). 2162–2170. 2 indexed citations
6.
Manier, Salomon, Alexander M. Lesokhin, Mohamad Mohty, et al.. (2023). P870: EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES. HemaSphere. 7(S3). e26808c7–e26808c7. 3 indexed citations
7.
Niesvizky, Rubén, Bertrand Arnulf, Mohamad Mohty, et al.. (2023). Clinical Factors Associated with Cytokine Release Syndrome and Dosing Recommendations for Restarting Elranatamab Following an Interruption. Blood. 142(Supplement 1). 3384–3384. 2 indexed citations
8.
Nooka, Ajay K., Alexander M. Lesokhin, Mohamad Mohty, et al.. (2023). EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN–DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES. Hematology Transfusion and Cell Therapy. 45. S405–S405. 1 indexed citations
9.
Brümmendorf, Tim H., Jörge E. Cortes, Dragana Milojković, et al.. (2022). Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 36(7). 1825–1833. 79 indexed citations
10.
Mamolo, Carla, et al.. (2021). An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia. Current Medical Research and Opinion. 37(5). 801–809. 7 indexed citations
11.
Cortes, Jörge E., Hervé Dombret, Akil Merchant, et al.. (2019). Glasdegib Plus Intensive/Nonintensive Chemotherapy in Untreated Acute Myeloid Leukemia: BRIGHT AML 1019 Phase III Trials. Future Oncology. 15(31). 3531–3545. 38 indexed citations
12.
13.
14.
Khoury, H. Jean, Carlo Gambacorti‐Passerini, Hagop M. Kantarjian, et al.. (2012). Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 24-Month Minimum Follow-up Update. Blood. 120(21). 3785–3785. 3 indexed citations
15.
Daud, Adil, Smitha Krishnamurthi, Mansoor N. Saleh, et al.. (2011). Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors. Clinical Cancer Research. 18(4). 1092–1100. 68 indexed citations
16.
Fox, Caroline S., Martin G. Larson, Ramachandran S. Vasan, et al.. (2005). Cross-Sectional Association of Kidney Function with Valvular and Annular Calcification. Journal of the American Society of Nephrology. 17(2). 521–527. 134 indexed citations
17.
Franklin, Stanley S., Jose R. Pio, Nathan D. Wong, et al.. (2005). Predictors of New-Onset Diastolic and Systolic Hypertension. Circulation. 111(9). 1121–1127. 185 indexed citations
18.
Fox, Caroline S., Qiong Yang, L. Adrienne Cupples, et al.. (2004). Genomewide Linkage Analysis to Serum Creatinine, GFR, and Creatinine Clearance in a Community-Based Population. Journal of the American Society of Nephrology. 15(9). 2457–2461. 112 indexed citations
19.
Wang, Thomas J., Martin G. Larson, Daniel Levy, et al.. (2003). Heritability and Genetic Linkage of Plasma Natriuretic Peptide Levels. Circulation. 108(1). 13–16. 69 indexed citations
20.
Wang, Thomas J., Martin G. Larson, Daniel Levy, et al.. (2003). Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality. Circulation. 107(23). 2920–2925. 1455 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wolfram Doehner Breakdown of academic impact, for papers by Stefan D. Anker Breakdown of academic impact, for papers by Inder S. Anand Breakdown of academic impact, for papers by Eldrin F. Lewis Breakdown of academic impact, for papers by Wiek H. van Gilst Breakdown of academic impact, for papers by Sunil Bhandari Breakdown of academic impact, for papers by Kosaku Nitta Breakdown of academic impact, for papers by Dominique Arveiler Breakdown of academic impact, for papers by Kenneth Dickstein Breakdown of academic impact, for papers by Kunitoshi Iseki
Rankless by CCL
2026